The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
about
Epidemiology and etiology of childhood pneumoniaWheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic reviewDevelopment of a vaccine against Staphylococcus aureusThe potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experienceInteraction between influenza virus and Streptococcus pneumoniae in severe pneumonia.Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.Contribution of vaccines to our understanding of pneumococcal disease.Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data.Procalcitonin and C-reactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malaria-endemic area.Standardized Interpretation of Chest Radiographs in Cases of Pediatric Pneumonia From the PERCH StudyThe effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South AfricaDevelopment of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa.Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system.Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of PeruGlobal, regional, and national estimates of pneumonia burden in HIV-infected children in 2010: a meta-analysis and modelling study.Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel.Epidemiology of viral-associated acute lower respiratory tract infection among children <5 years of age in a high HIV prevalence setting, South Africa, 2009-2012Vaccines for invasive fungal infectionsCost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese ChildrenHospital admissions from a pediatric HIV care and treatment program in Malawi.Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996-2011: light at the end of the tunnel?A Pneumococcal Protein Array as a Platform to Discover Serodiagnostic Antigens Against Infection.Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Clinical and Hypoxemic Childhood Pneumonia over Three Years in Central Malawi: An Observational Study.Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings.Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural ThailandIncidence of Pneumococcal Pneumonia Among Adults in Rural Thailand, 2006-2011: Implications for Pneumococcal Vaccine ConsiderationsCommunity-acquired pneumonia requiring hospitalization among U.S. children.Enhanced Diagnosis of Pneumococcal Bacteremia Using Antigen- and Molecular-Based Tools on Blood Specimens in Mali and Thailand: A Prospective Surveillance Study.Pneumococcal conjugate vaccines: emerging clinical information and its implications.Vaccines to prevent pneumonia and improve child survival.Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011.Management of community-acquired pneumonia in HIV-infected children.Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children.Seven-valent pneumococcal conjugate vaccines for developing countries.
P2860
Q22241278-0D2A77B5-AB49-4D38-B334-15B34CD997A7Q26796334-5DB196D4-3D4C-48B7-BED5-660FA944B95EQ27015365-D915B6B4-1B81-4D2D-935B-4704DE45FE58Q28088507-0BA6AF40-3C15-4941-B7BE-8032F588645AQ30228581-E01A6FE3-EE1D-4625-9888-36995C80A448Q30235055-93AABE17-EA3E-479A-88D7-83988EAB612AQ30406750-9C696D2D-70E3-45E7-B6DB-A29B37B91214Q31072053-CF74E606-24B5-4687-9563-E0B260C59BA8Q33728623-BF4AB5AB-5777-4B2A-B66B-26CB27210568Q33736986-3BD10636-BC25-40E7-9B2E-D1331220334DQ33754518-D916FE35-CDEA-4006-8E83-1EABC5F19028Q33865533-53699BBE-F4B4-42F9-8675-0DB8AC0E7AB9Q34124926-EDDF21B8-210B-439C-8F19-A12F7ADA71BCQ34137232-24F6B4BB-9A40-4801-BFDB-D67EBBCBBFBFQ34493821-AF6E2C4F-8499-4E31-9A7B-277CB389F406Q34563804-9B8B984A-9492-4B5E-AA9A-D667A52CF848Q34771479-97FD662B-6063-4CB0-9FB6-45E444406B66Q34772743-BF3AA6AE-E0EA-4C45-B2BD-A78EA91EABBBQ35161720-10998030-D7CA-4F8B-B760-DD6DCD7FA643Q35186834-E1FFF144-4E1F-45B0-B681-A457986370CDQ35910124-1FA1D91E-CDB2-491C-9870-31D11E3195D3Q36009704-F71B3246-0F87-42C5-B8F6-9596D9425A0BQ36113585-0F2DA281-3DE7-4BB3-9A5D-443F045F6BE6Q36133960-F047DD4C-510F-4F2A-9E37-8A7D8B95DE03Q36239337-DBFD67D4-86E7-4ED2-9748-E3FEB2C43437Q36288227-EA7CAC21-F755-4736-9D51-5A8F30BE7087Q36341657-0C6AF147-01F3-469D-BD0F-72E6E2B2D49FQ36359206-DFBFD8B3-8D2D-4DAC-8C46-CF8276DC4807Q36420016-9BD4F297-9491-494B-86C6-6074F49B0C61Q36575413-58DE528C-5F1E-4D72-8DB8-F3F230888DACQ36600371-B7898D50-E27B-45DF-873F-29962FCE9268Q37108802-AF339743-08EE-4F22-A316-BB4326043B29Q37264943-01E1B49B-B324-47AC-B0BA-DB19BC5DBDDDQ37316015-6A899E66-DA3D-4217-BFB1-A07D61D4716FQ37335166-D828FC64-53A1-4DAF-A4AF-F522CDBD25B5Q37463218-59246170-A627-4B93-9E62-923967BE2C04Q37475459-BF803E56-3DA3-45EB-B486-F8FE42A13D7CQ37516888-990E6EC2-8B12-46FF-9E3C-173F2C63B6E4Q37548453-3BFD1A72-F396-49C7-A8C4-646966CFB654Q37559638-D391349C-2178-4BD8-85C3-AC8A6E6F977D
P2860
The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The impact of a 9-valent pneum ...... cted and -uninfected children.
@en
The impact of a 9-valent pneum ...... cted and -uninfected children.
@nl
type
label
The impact of a 9-valent pneum ...... cted and -uninfected children.
@en
The impact of a 9-valent pneum ...... cted and -uninfected children.
@nl
prefLabel
The impact of a 9-valent pneum ...... cted and -uninfected children.
@en
The impact of a 9-valent pneum ...... cted and -uninfected children.
@nl
P50
P356
P1476
The impact of a 9-valent pneum ...... cted and -uninfected children.
@en
P304
P356
10.1086/429828
P407
P577
2005-04-07T00:00:00Z